---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-21-001975"
form_type: "8-K"
ticker: "TCRT"
cik: "0001107421"
company_name: "Alaunos Therapeutics, Inc."
filed_at: "2021-10-01T23:59:59+00:00"
generated_at: "2026-06-28T23:45:51.231102+00:00"
event_type: "leadership"
sentiment: "negative"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Ziopharm CAO Kevin Lafond to exit Nov 8 amid restructuring

## Summary
- Kevin G. Lafond, Sr. VP Finance, CAO and Treasurer, separating effective Nov 8, 2021.
- Severance payment of approximately $0.2 million upon separation.
- Departure is part of a restructuring to advance the TCR program.

## SEC filing metadata
- accession: 0000950170-21-001975
- form_type: 8-K
- ticker: TCRT
- cik: 0001107421
- company_name: Alaunos Therapeutics, Inc.
- filed_at: 2021-10-01T23:59:59+00:00
- event_type: leadership
- sentiment: negative
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1107421/000095017021001975/0000950170-21-001975-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1107421/000095017021001975/ziop-20211001.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-21-001975
- JSON: https://secwatch.observer/filing/0000950170-21-001975.json
- Plain text: https://secwatch.observer/filing/0000950170-21-001975.txt

## Key facts
- Executive change
  Kevin G. Lafond departed as Sr. Vice President Finance, Chief Accounting Officer and Treasurer at Alaunos Therapeutics, Inc..
  - Action: separating
  - Role: Sr. Vice President Finance, Chief Accounting Officer and Treasurer
  source text: Kevin G. Lafond, Sr. Vice President Finance, Chief Accounting Officer and Treasurer, is separating from the Company effective November 8, 2021
  evidence_url: https://www.sec.gov/Archives/edgar/data/1107421/000095017021001975/0000950170-21-001975-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.